ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

by | Mar 16, 2026 | Clinical Trials | 0 comments

​ Conditions: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage III; Merkel Cell Carcinoma, Stage IV

Interventions: Drug: ASTX727 + retifanlimab

Sponsors: University of Wisconsin, Madison

Not yet recruiting Conditions: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage III; Merkel Cell Carcinoma, Stage IV
Interventions: Drug: ASTX727 + retifanlimab
Sponsors: University of Wisconsin, Madison
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *